Medicina y salud
Disciplina temática
Oslo University Hospital
Oslo, NoruegaPublicaciones en colaboración con investigadores/as de Oslo University Hospital (90)
2024
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
-
International Delphi Consensus Study on disposable single-use endoscopy: A path to clinical adoption
Digestive and Liver Disease, Vol. 56, Núm. 2, pp. 322-329
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411
-
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
Nature Genetics, Vol. 56, Núm. 1, pp. 27-36
-
The Pediatric and Young Adult Choroidal and Ciliary Body Melanoma Genetic Study, A Survey by the European Ophthalmic Oncology Group
Investigative Ophthalmology and Visual Science, Vol. 65, Núm. 4
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Analysis of ATG4C function in vivo
Autophagy, Vol. 19, Núm. 11, pp. 2912-2933
-
Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)
npj Parkinson's Disease
-
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696
-
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
npj Parkinson's Disease, Vol. 9, Núm. 1
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
siRNA screening reveals that SNAP29 contributes to exosome release
Cellular and Molecular Life Sciences, Vol. 80, Núm. 7
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Clinical Outcomes After Total Pancreatectomy: A Prospective Multicenter Pan-European Snapshot Study
Annals of surgery, Vol. 276, Núm. 5, pp. e536-e543
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))
Clinical Lymphoma, Myeloma and Leukemia